In addition to the patient education database, guidelines for the interaction of patient organizations with ethics, health technology assessment, regulatory bodies and industry are being developed with the goal of being released later in the year.
Following the success of its Patient Expert Training Course, the European Patients’ Academy (EUPATI) has announced the launch of its second core product: the Internet Toolbox on Medicines R&D.
"The new knowledge base at www.eupati.eu comprises of a wide range of content covered by the organization’s course in seven languages, including 3,000 articles, images, presentations, fact sheets and interface strings with a volume of around 1 million words in 100 topic areas. A total of 40 external volunteer translation reviewers have double-checked everything before it gets published, according to EUPATI Director Jan Geissler."
In September 2015, the platform was made available in a password-protected "soft launch" to selected national members and advisers. A functional test, experience test and accessibility test was carried out: 83% agreed or strongly agreed that the website is easy to use, 75% that they are able to find what they need quickly, and 91% that they would recommend it to a friend.
EUPATI now has eight national networks (U.K., Ireland, Spain, Italy, Austria, France, Malta, and Luxembourg), with three further launches expected in early 2016 (Germany, Switzerland, Poland). These groups have are preparing various activities, including webinars, information days, training sessions, and social media campaigns. Other networks are planned in Denmark, Greece, Portugal, and Slovakia.
“Patient preferences, quality of life, patients' unmet needs are often not reflected when research and trials are designed without patient input, leading to delayed research and generation of meaningful data, to trials that don't recruit and that patients don't accept,” noted Geissler. “It is difficult to do risk/benefit assessments without asking patients, as doctors' and patients' perceptions so often differ very significantly. Hence, it is of key importance to involve patients all across the development lifecycle, and especially in early phases when research priorities are set and research/trials are designed e.g. when protocols are written, to make sure that research truly meets patients' needs and expectations.”
Clinicians must involve patients at an early stage to make sure the trials are designed around patients’ needs, risks emerging from new data are assessed with patient input, and trial results are communicated to participants and spread within the community, he added.
EUPATI’s first course began in October 2014, and 46 trainees completed it successfully in January 2016. Only two drop-outs were reported. The second 14-month course started in October 2015 with 60 trainees from 33 countries and 28 disease areas. For further details about the participants in the training program, click here.
Finally, guidelines for the interaction of patient organizations with ethics, health technology assessment, regulatory bodies and industry are being developed. The consultation process started in December and will run until February 2016. The completed guidelines will be released later in the year.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.